| abstract |
Compounds that form covalent bonds with brutonyl tyrosine kinase (Btk) are disclosed. An irreversible inhibitor of Btk is also described. A method for producing a compound is disclosed. Also disclosed are pharmaceutical compositions comprising the compounds. Methods of using Btk inhibitors to treat autoimmune diseases or conditions, xenogenic immune diseases or conditions, cancer, including lymphomas, and inflammatory diseases or conditions, alone or in combination with other therapeutic agents, are disclosed. |